Cookie use on MRCVSonline
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive all cookies.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Aservo® EquiHaler® now available in the UK and Ireland
The inhaler marks more than a decade of collaboration between human pharma and animal health businesses.

Product allows medication to be inhaled deep into horses’ lungs.
 
The first inhaled treatment for severe equine asthma is now available in the UK and Ireland.

Manufactured by Boehringer Ingelheim, the Aservo® EquiHaler® marks more than a decade of collaboration between human pharma and Boehringer’s animal health business.

The inhaler incorporates Soft Mist Technology®, which is found in the Respimat® inhaler used in human respiratory disease. This allows the active ingredient to be inhaled deep into the horses’ lungs.

"It's another industry first and is a strong indicator of the commitment that Boehringer Ingelheim has to the health and welfare of horses, and to the investment that we make into continuing to advance therapies through collaboration and innovation,” commented Dr Marc Laemmer, head of equine in UK & Ireland.

“We understand that a product launch in this challenging time for the veterinary profession may seem surprising, but we have had such strong demand from equine vets for the product that we have committed to making Aservo® EquiHaler® available. Our team of territory managers and vet advisers will conduct remote meetings with customers to make sure that they have the information and support they require.”

He continues: “The launch of Aservo® EquiHaler® is a prime example of leveraging innovation efforts of both our human and animal businesses. This has been a strength of ours and I'm excited that we are continuing to further increase the delivery of innovative solutions for horse owners and vets."

The active ingredient in the Aservo® EquiHaler® is ciclesonide - a corticosteroid that is activated directly in the lung, reducing the lower airway inflammation associated with severe equine asthma and reducing the risks commonly associated with systemic corticosteroids.

It does not use a propellant, meaning that using the device does not contribute to harmful greenhouse gas emissions. It has also been manufactured from 50 per cent recycled materials.

Featuring an ergonomic handle, dosing lever, and nostril adapter, the Aservo® EquiHaler®  has been awarded the prestigious Red Dot Award for Product Design.



Become a member or log in to add this story to your CPD history

Defra extends applications to Zoo Animals Fund

News Story 1
 Defra has extended the deadline for applications for the 100 Million Zoo Animals Fund until 26 February 2021.

Launched in June 2020, the fund provides financial support for zoos and aquariums that have experienced a drop in income caused by the coronavirus pandemic. Grants of up to 730,000 are available, which can be used to pay for essential costs and maintenance, including veterinary care, medicines, animal feed and staffing.

More information about the fund and details of how to apply can be found here

Click here for more...
News Shorts
APHA confirms eighth case of highly pathogenic avian influenza in England

The Animal & Plant Health Agency (APHA) has identified an eighth case of highly pathogenic avian influenza (HPAI) H5N8 in poultry in England.

Confirmed on Tuesday (15 December), the outbreak was found in captive birds and poultry at a premises near Willington, South Derbyshire. A 3km Protection Zone and a 10km Surveillance Zone have been placed around the infected premises to limit the risk of the disease spreading.

Further information about the outbreaks and the latest government advice can be found at gov.uk